by
Gus Iversen, Editor in Chief | May 07, 2025
Chrysalis, SHINE's large-scale irradiation facility, is set to become the largest isotope production facility in the world.
SHINE Technologies has announced plans to acquire the SPECT business of Lantheus, a move aimed at broadening its foothold in the nuclear medicine market.
The deal, which includes the manufacturing operations at Lantheus’ North Billerica, Massachusetts site, is expected to strengthen SHINE’s medical isotope production and distribution capabilities.
The Janesville, Wisconsin-based company, which focuses on fusion-based medical isotope production, said the acquisition will integrate Lantheus' single-photon emission computed tomography (SPECT) portfolio with its own growing suite of radiopharmaceuticals. Lantheus, headquartered in Bedford, Massachusetts, is recognized for its leadership in diagnostic imaging agents, including technetium-99 (Tc-99).
Ad Statistics
Times Displayed: 118498
Times Visited: 6883 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“This marks a major milestone on our journey to improve lives through fusion technology,” said Greg Piefer, founder and CEO of SHINE. “By integrating Lantheus’ SPECT business and talented team, we will expand our product portfolio, accelerate our path to market for new isotopes, and increase our market share.”
The transaction deepens a longstanding partnership between the two companies, both of which have emphasized reliable access to key medical isotopes. SHINE noted that the acquisition aligns with its broader strategy to reinforce the global supply of critical isotopes, including molybdenum-99 (Mo-99) and lutetium-177 (Lu-177).
Brian Markison, CEO of Lantheus, said the agreement allows the company to focus on expanding its diagnostics and therapeutics pipeline. “We are confident that SHINE’s expertise in isotope production as well as their commitment to growth and patient access position them well to continue our legacy with the SPECT business,” he said.
SHINE is also advancing its large-scale irradiation facility, Chrysalis, which is expected to become one of the world’s largest isotope production sites. The facility is designed to bolster the availability of Mo-99 and Lu-177, supporting nuclear medicine procedures worldwide.
Financial terms of the agreement were not disclosed.
